Human Rights Policies
Daiichi Sankyo Group Corporate Conduct Charter declares "Respect for Human Rights" in Article 4, "Responsible Procurement" in Article 2, "Respect the diversity of Employees, ensure a healthy and safe working environment and do not tolerate harassment and discrimination" in Article 5, and "Executives of the Group ensure it is understood by all Group companies, and encourage behavior based on the principles of this Charter to the business partners of Daiichi Sankyo Group" in Article 10.
To respect human rights of all people and comply with labor standards is defined as the Daiichi Sankyo Group Employee Code of Conduct that specifies the principles by which all executives and employees are expected to conduct their work.
We adhere to the Universal Declaration of Human Rights and the core labor standards of the International Labour Organization (ILO), which are representative of the rights of employees, as well as the United Nations Guiding Principles on Business and Human Rights, which call on us to protect, respect and remedy human rights. In addition, we stringently manage personal information when conducting human genome and gene analysis research, obtain informed consent and observe good clinical practices of the coalition of Japan, the United States, and Europe that is known as the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-GCP), which are based on the spirit of the world Medical Association’s Declaration of Helsinki, a statement of ethical principles for medical research involving human subjects. We believe that adhering to these standards is an important task to be addressed in protecting human rights as a life-science company. Various types of training are provided in this regard.
In April 2012, the Company signed the United Nations Global Compact. We support and strive to achieve its Ten Principles in four areas including freedom of association and collective bargaining, preventing forced labor, eliminating child labor, and preventing discrimination in hiring and work. We have also created tools to help facilitate understanding with regard to the Ten Principles in the four areas within the United Nations Global Compact, and these tools are deployed at Japan Daiichi Sankyo and overseas group companies.
In addition to the United Nations Global Compact, we incorporate initiatives in our business regarding the human rights of children not only in the prohibition of child labor and the protection of young workers of children but also in conducting research and development and clinical trials of pediatric formulations and vaccines for children in light of the United Nations Guiding Principles on Business and Human Rights, the Ten Principles of the United Nations Children’s Rights and Business Principles.
Building a System to Demonstrate Due Diligence With Regard to Human Rights
As a global pharmaceutical group of companies, the Daiichi Sankyo Group is promoting business activities that take into account the human rights of diverse stakeholders, including patients and their family, doctors and other healthcare providers, employees, suppliers, and local communities by complying with the Declaration of Helsinki and other R&D ethics, promoting sustainable procurement including ensuring human rights in our supply chain, respecting the diversity of employees, and ensuring a healthy and safe working environment without harassment and discrimination. We shall conduct Human Rights due diligence based on our Human Rights Policy.
Respect for Human Rights
Human Rights of Business Partners
In its Business Partner Code of Conduct, the Daiichi Sankyo Group stipulates its expectations of business partners to comply with and respect various international norms, including human rights. Based on this Code, Daiichi Sankyo Group conducts periodic CSR Self-Assessment Questionnaire Surveys, to confirm the status of business partners' responses to human rights in their businesses.
Ethics in Clinical Trials
Daiichi Sankyo conducts clinical trials in accordance with the Declaration of Helsinki that defines the standards for ethical medical research involving human subjects, while also adhering to ICH-GCP (Good Clinical Practice from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) and complying with the applicable regulations of relevant countries. This means that clinical trials are only conducted after obtaining voluntary informed consent from participants.
All clinical trials sponsored by Daiichi Sankyo are evaluated in terms of ethical standards and scientific validity based on internal review processes. In particular, we ensure that our first in human study is an appropriate through clinical trial review meetings that include employees who are qualified physician as review members. Furthermore, clinical trials are conducted after an external independent committee (Institutional Review Board / Independent Ethics Committee) also reviews the same content (human rights of trial subjects, etc.) and approves the conduct of clinical trials.
Daiichi Sankyo provides training programs on GCP and Ethics related to clinical trials to people who are engaged in clinical trials.
R&D & PV Quality Assurance Department conducts audits of the Company’s clinical trial activities to promote appropriate correction and preventive measures.
Collaboration with Contract Research Organizations
Daiichi Sankyo has defined the Global Policy of Clinical Trials Standards and ensure the highest degree of respect for the human rights and well-being of all individuals participating in clinical trials. At the same time, we guarantee that our clinical trials are ensured scientifically high quality, reliable and ethically sound. We also plan and conduct all clinical trials in accordance with GCP and in compliance with local regulations in each country.
In case of that Daiichi Sankyo outsources part or all of clinical trial activities to contract research organizations (CROs), Daiichi Sankyo policies and standards for clinical trials are applied. For this reason, we assess CROs as part of the selection process to determine if they have the necessary capabilities to perform clinical trials and CROs are selected based on the results of assessments. Daiichi Sankyo requires the CRO staff to be trained on Daiichi Sankyo policies and standard procedures. After contracts have been executed, we continue monitoring their performance on a regular basis, as well as maintaining oversight of their services. Our R&D & PV Quality Assurance Department conducts independent audits to determine whether clinical trial services are appropriately outsourced to CROs.
Employee Human Rights Initiatives
The Daiichi Sankyo Group respects the diversity of employees, ensures a healthy and safe working environment and does not tolerate harassment and discrimination. In Japan, we conduct ongoing training related to human rights for all employee groups–from newly hired employees to management. In addition to implementing daily awareness raising activities, we have implemented training that uses case studies and is designed to improve the counseling skills of the Harassment Call Center staff. This staff is stationed at each work location within Japan and at the labor union. Each and every alleged violation is treated seriously; we emphasize appropriate behavior and seek the opinions of external individuals, including legal counsel, and put necessary preventative measures in place to avoid a recurrence. Our other Daiichi Sankyo Group companies have made hotlines available 24 hours a day and a like in each country and region globally for consultation and reports on issues such as human rights and labor issues. These hotlines can be available to individuals both inside and outside of the Group companies, and assistance is provided as needed. We shall not take reprisals against any person who report in good faith through the hotlines, protect their confidentiality, and accept anonymous reports.
UK Modern Slavery Act 2015
Daiichi Sankyo Group reported the initiatives to prevent modern slavery and human trafficking in our business activities including our supply chain.
Slavery and Human Trafficking Statement (Fiscal Year 2019).pdf